A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

Not specified

Study Completion Date

September 30, 1997

Conditions

HIV Infections

Interventions

BIOLOGICAL

Aluminum hydroxide

BIOLOGICAL

QS-21

BIOLOGICAL

rgp120/HIV-1MN

Trial Locations (5)

Univ. of Rochester AVEG, Rochester

JHU AVEG, Pittsburgh

Vanderbilt Univ. Hosp. AVEG, Nashville

St. Louis Univ. School of Medicine AVEG, St Louis

UW - Seattle AVEG, Seattle

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH